Brain Metastases clinical trials

Explore recruiting brain metastases clinical trials.

Recruiting brain metastases studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Brain Metastases trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

SGM-CBM: A feasibility study of SGM-101, a fluorochrome-labeled anti-carcinoembryonic antigen monoclonal antibody for the intraoperative detection of colorectal brain metastases.

Netherlands

Therapeutic exploratory (Phase II) EU CTIS Study details

A multicenter, open-label, non-comparative, single-arm, phase II trial of datopotamab deruxtecan for non-squamous non-small cell lung cancer patients with active brain metastases (The TUXEDO-5 Study)

Spain, Austria

Therapeutic exploratory (Phase II) EU CTIS Study details

STRIDER: A phase II Study evaluaTing intRacranial effIcacy of JDQ443 in patiEnts with KRAS G12C+ NSCLC and bRain metastases

Netherlands

Therapeutic exploratory (Phase II) EU CTIS Study details

Imaging Perfusion Restrictions from Extracellular Solid Stress - An open-label losartan study (ImPRESS)

Norway

Therapeutic exploratory (Phase II) EU CTIS Study details

Comparison of 18F-Fluciclovine PET versus 18F-Fluoroethyltyrosine PET in patients with newly diagnosed cerebral gliomas, recurrent cerebral gliomas and brain metastases – an open label single centre single arm prospective basket trial

Germany

Therapeutic exploratory (Phase II) EU CTIS Study details

Multicenter open-label, phase II trial, to evaluate the efficacy and safety of nal-IRI for progressing brain metastases in patients with HER2-negative breast cancer.

Spain

Therapeutic exploratory (Phase II) EU CTIS Study details

Brain Metastases trials by city

Brain Metastases in Toronto Brain Metastases in Vancouver Brain Metastases in Montreal Brain Metastases in Calgary Brain Metastases in Edmonton Brain Metastases in Ottawa Brain Metastases in Winnipeg Brain Metastases in Quebec City Brain Metastases in Hamilton Brain Metastases in Kitchener Brain Metastases in London Brain Metastases in Halifax Brain Metastases in New York Brain Metastases in Los Angeles Brain Metastases in Chicago Brain Metastases in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease